A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controlsReportar como inadecuado




A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Arthritis Research and Therapy

, 18:86

First Online: 12 April 2016Received: 12 January 2016Accepted: 23 March 2016

Abstract

BackgroundRA and CVD both have inflammation as part of the underlying biology. Our objective was to explore the relationships of GlycA, a measure of glycosylated acute phase proteins, with inflammation and cardiometabolic risk in RA, and explore whether these relationships were similar to those for persons without RA.

MethodsPlasma GlycA was determined for 50 individuals with mild-moderate RA disease activity and 39 controls matched for age, gender, and body mass index BMI. Regression analyses were performed to assess relationships between GlycA and important markers of traditional inflammation and cardio-metabolic health: inflammatory cytokines, disease activity, measures of adiposity and insulin resistance.

ResultsOn average, RA activity was low DAS-28 = 3.0 ± 1.4. Traditional inflammatory markers, ESR, hsCRP, IL-1β, IL-6, IL-18 and TNF-α were greater in RA versus controls P < 0.05 for all. GlycA concentrations were significantly elevated in RA versus controls P = 0.036. In RA, greater GlycA associated with disease activity DAS-28; RDAS-28 = 0.5 and inflammation RESR = 0.7, RhsCRP = 0.7, RIL-6 = 0.3: P < 0.05 for all; in BMI-matched controls, these inflammatory associations were absent or weaker hsCRP, but GlycA was related to IL-18 RhsCRP = 0.3, RIL-18 = 0.4: P < 0.05. In RA, greater GlycA associated with more total abdominal adiposity and less muscle density Rabdominal-adiposity = 0.3, Rmuscle-density = −0.3, P < 0.05 for both. In BMI-matched controls, GlycA associated with more cardio-metabolic markers: BMI, waist circumference, adiposity measures and insulin resistance R = 0.3-0.6, P < 0.05 for all.

ConclusionsGlycA provides an integrated measure of inflammation with contributions from traditional inflammatory markers and cardio-metabolic sources, dominated by inflammatory markers in persons with RA and cardio-metabolic factors in those without.

KeywordsRheumatoid arthritis Inflammation Biomarker Metabolic syndrome Glycosylation AbbreviationsBMIBody mass index

CTComputed tomography

CVDCardiovascular disease

DASESR-28Disease Activity Score with 28-joint count using the erythrocyte sedimentation rate

ESRErythroctye sedimentation rate

HAQ-DIHealth Assessment Questionnaire—Disability Index

HOMAHomeostasis model assessment

hsCRPHigh-sensitivity C-reactive protein

ILInterleukin

ISinsulin sensitivity

IVGTTIntravenous glucose tolerance test

NMRNuclear magnetic resonance

PREVENDPrevention of Renal and Vascular End-stage Disease study

RARheumatoid arthritis

T2DMType 2 diabetes mellitus

TNFαTumor necrosis factor alpha

WHSWomen’s Health Study

Download fulltext PDF



Autor: David B. Bartlett - Margery A. Connelly - Hiba AbouAssi - Lori A. Bateman - K. Noelle Tune - Janet L. Huebner - Virgini

Fuente: https://link.springer.com/







Documentos relacionados